Crohn’s disease has been beating up on you long enough. For adults with moderately to severely active Crohn’s disease, remission can start with STELARA®.
Only STELARA® starts with a one-time intravenous (IV) infusion to help reduce symptoms of Crohn’s disease, followed by subcutaneous maintenance injections to help keep the disease under control.
*Cumulative exposure from September 2009 through August 2016. Uses include plaque psoriasis, psoriatic arthritis, and others.
Clinical studies included patients who were new to, had experience with, or did not respond to biologics.† Of the patients who were new to, or had experience with biologics, the majority found relief from their Crohn's disease symptoms in just 6 weeks after the one-time intravenous (IV) infusion of STELARA®, with noticeable improvement as early as 3 weeks. Additionally, the majority of those continuing treatment with STELARA® subcutaneous maintenance doses were in remission through the end of the one-year study.
STELARA® is not right for everyone. Only your doctor can decide if STELARA® is right for you. Individual results may vary.
†Tumor necrosis factor blocker (anti-TNF agent).
Watch How Terrie Found Relief With The Help Of STELARA®
Results may vary. STELARA® may not be right for everyone. Only your doctor can decide if STELARA® is right for you.
Crohn’s disease is an autoimmune condition. Even though the exact cause of Crohn’s disease is unknown, potential drivers of Crohn’s disease have been linked to a combination of several factors including your immune system, genetics, and the environment.
Your immune system, which normally responds to foreign threats, microorganisms, and intestinal bacteria, is out of balance and mounts inflammatory attacks against your own body. It is believed that substances in the intestines are mistaken for invading substances. The immune system causes temporary inflammation to combat these substances and lessens the response as you regain your health. In Crohn’s disease, the inflammation can persist long after the time when the immune system should have completed its response.
There are many different naturally occurring proteins in the body that contribute to inflammation. Patients with Crohn's disease are found to have elevated levels of two of these proteins, IL-12 and IL-23.
STELARA® is the only FDA-approved medicine that targets IL-12 and IL-23, which are thought to be associated with gastrointestinal inflammation in Crohn's disease.
Our Care Coordinators can help you start, save, and stay on STELARA®.